6/13/2014 8:05:04 AM
TARRYTOWN, N.Y., June 12, 2014 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) chief executive officer Mark Baker will comment on the FDA Advisory Committee meeting held this week, in a conference call tomorrow, Friday, June 13, at 8:30 a.m. Eastern Time.
The Advisory Committee meeting was originally announced in June 2013 in response to the appeal by Progenics' collaboration partner, Salix Pharmaceuticals (Nasdaq:SLXP), of the U.S. Food and Drug Administration's July 2012 Complete Response Letter in respect of Salix's supplemental New Drug Application for Relistor® subcutaneous injection for treatment of opioid-induced constipation in patients with chronic non-cancer pain. The FDA has stated that it will take action under the appeal within 30 days after receiving input from the Committee.
Help employers find you! Check out all the jobs and post your resume.
comments powered by